Table 1.

Anti-HCMV activity of the selected CDK inhibitors (µM).

Target	Compound	EC50 a	CC50 b	SI c
vCDK/pUL97	MBV	0.35 ± 0.42	>100	>250
CDK2	CDK2 Inh II	6.33 ± 2.80	>100	>16
CDK7	LDC4297	0.009 ± 0.002	>10	>1000
CDK8	SEL120	0.079 ± 0.001	5.90 ± 3.85	75

^a Half-maximal efficacy (EC₅₀) against HCMV AD169-GFP was determined via the GFP-based replication assay; these EC₅₀ values represent the mean ± SD of ≥2 biological replicates. ^b Half-maximal cytotoxicity in mock-infected HFFs was determined via the Neutral Red assay; these CC₅₀ values represent the mean ± SD of ≥biological replicates. ^c Selectivity index was calculated as the ratio CC₅₀/EC₅₀. EC₅₀ and EC₅₀ values are presented in micromolar concentrations.